ARCHIVES

Oncologists Don’t Demand Increased Survival When Ordering Expensive Drugs, Survey Finds

This article is from The Cancer Letter archive.

Vol. 38 No. 15 | April 13, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

NCI Spearheads Asbestos Alert

June 16, 1978

Kennedy Plans One Year Act Renewal, Followed By Three Year Bill; Hearing Scheduled Feb. 8

February 3, 1978

NIH-funded HapMap consortium publishes first phase of catalog.

October 28, 2005

UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer

June 26, 2013

NCI Cancer Prevention Fellowship Program

April 28, 2000